GlassScriptPhysician profile
Linsey Philip
NPI 1053304469
$8,006.76
in general payments reported to CMS, 2019-2025
34 companies · $801 in 2025
The $801 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,357 · 2020: $394 · 2021: $218 · 2022: $1,058 · 2023: $782 · 2024: $1,397 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,199.90 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $906.79 | 2019-2025 | Dovato, Apretude |
| Astrazeneca Pharmaceuticals LP | $865.02 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $621.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $448.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $437.79 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.62 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Products, LP | $347.18 | 2019-2022 | |
| Mylan Specialty L.P. | $317.49 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $264.10 | 2019-2020 | |
| Abbvie INC. | $246.54 | 2019-2024 | |
| Allergan, INC. | $199.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $178.50 | 2025 | Rexulti |
| Amarin Pharma, INC. | $167.84 | 2019 | |
| Phathom Pharmaceuticals, INC. | $165.59 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $154.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.23 | 2021 | |
| Edwards Lifesciences Corporation | $122.23 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $118.55 | 2024 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $112.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $110.00 | 2019 | |
| Inari Medical, INC. | $101.09 | 2022 | |
| Janssen Biotech, INC. | $78.93 | 2019-2020 | |
| Napo Pharmaceuticals INC | $50.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.64 | 2019 | |
| Melinta Therapeutics, LLC | $48.63 | 2019 | |
| Lilly USA, LLC | $42.88 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.62 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $25.98 | 2019 | |
| Pfizer INC. | $21.93 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.45 | 2019 | |
| Aimmune Therapeutics, INC. | $19.91 | 2024 | |
| Astellas Pharma US INC | $17.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linsey Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.